EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Seattle Biotech, Unite!

Seattle Biotech, Unite!

Photo by Benjamin Romano / Xconomy

Name Badges

Name Badges

Photo by Benjamin Romano / Xconomy

Steps Toward Cures...

Steps Toward Cures...

Gary Gilliland, President & Director, Fred Hutchinson Cancer Research Center, in conversation with Xconomy National Biotech Editor Alex Lash.

Photo by Benjamin Romano / Xconomy

...Start Here

...Start Here

Photo by Benjamin Romano / Xconomy

Innovation’s Sources

Innovation’s Sources

From left, Gary Gilliland, Fred Hutchinson Cancer Research Center; David Poston, Allen Institute; Vikram Jandhyala, UW CoMotion; Charlotte Hubbert, The Bill & Melinda Gates Foundation; and Alex Lash, Xconomy

Photo by Benjamin Romano / Xconomy

Making Connections

Making Connections

Photo by Benjamin Romano / Xconomy

Networking Break

Networking Break

Photo by Benjamin Romano / Xconomy

More networking

More networking

Photo by Benjamin Romano / Xconomy

Lee Hood and Bob Nelsen

Lee Hood and Bob Nelsen

Leroy Hood and Bob Nelsen chat during a networking break at Xconomy's Seattle biotech forum, May 2015.

Photo by Benjamin Romano / Xconomy

Coffee Talk

Coffee Talk

Photo by Benjamin Romano / Xconomy

Adaptive Biotechnologies CEO Chad Robins at Xconomy's seattle biotech forum, May 2015

Adaptive Biotechnologies CEO Chad Robins at Xconomy's seattle biotech forum, May 2015

Adaptive Biotechnologies CEO Chad Robins at Xconomy's Seattle biotech forum, May 2015

Photo by Benjamin Romano / Xconomy

High-density Networking

High-density Networking

Photo by Benjamin Romano / Xconomy

Tech vs. Biotech

Tech vs. Biotech

Madrona's Matt "Pacquiao" McIlwain vs. ARCH's Bob "Mayweather" Nelsen. Or was it the other way around?

Photo by Benjamin Romano / Xconomy

Networking Break

Networking Break

Photo by Benjamin Romano / Xconomy

David Poston, COO, of the Allen Institute for Brain Science, left, talks with Dominic Suciu of G-Genomics.

Photo by Benjamin Romano / Xconomy

Leroy Hood

Leroy Hood

The National Medal of Science winner fields questions after his presentation.

Photo by Benjamin Romano / Xconomy

Xconomy Seattle — 

Seattle biotech leaders gathered at the Fred Hutchinson Cancer Research Center on Wednesday received a generally sunny view of the industry in the region, despite the ongoing laments about our lack of a true anchor tenant and lackluster state-level support.

The crowd erupted in cheers when Adaptive Biotechnologies CEO Chad Robins announced a $195 million funding round, reported earlier in the day. Robins, whose company makes tools to help understand the immune system, said he is frequently asked, “Are you looking for gold or providing pickaxes and shovels?” His answer to that very Seattle question: “Both.”

Fred Hutch president and director Gary Gilliland talked about the coming “tidal wave” of immunotherapeutic approaches to cancer treatment, and the CEOs of two Seattle companies riding that wave—Hans Bishop of Juno Therapeutics and Carlos Paya of Immune Design—provided in-depth looks at their approaches.

Madrona Venture Group managing director Matt McIlwain and ARCH Venture Partners managing director Bob Nelsen squared off on tech versus biotech in Seattle. Nelsen noted how the tech boom is making biotech more expensive, particularly when it comes to real estate. (Exhibit A being Expedia’s purchase of the Helix campus.) The sectors are also increasingly in competition for people with computer- and data-science skills.

But, as McIlwain and Nelsen noted, that is also an area for potential collaboration. Another is in the realm of healthcare IT.

The event culminated with Leroy Hood, president of the Institute for Systems Biology, who gave an update on a decades-long “longitudinal” comprehensive survey of the state of health of up to 100,000 people. Results from the first 100 volunteers are revealing what Hood described as lots of unforeseen connections in the data. He termed them “the dark matter of human physiology.”

There was much more, which our National Biotech Editor Alex Lash, who organized and emceed the event, will report on in coming days.

Thanks again to all of our speakers, attendees, and sponsors.